Overview
Dr. Susanna Naggie completed her undergraduate degrees in chemical engineering and biochemistry at the University of Maryland, College Park, and her medical education at Johns Hopkins School of Medicine. She conducted her internal medicine and infectious diseases fellowship training at Duke University Medical Center, where she also served as Chief Resident. She joined the faculty in the Duke School of Medicine in 2009. She is a Professor of Medicine and currently holds appointments at the Duke University School of Medicine, at the Duke Clinical Research Institute, and at the Durham Veterans Affairs Medical Center. Dr. Naggie is a clinical investigator with a focus in clinical trials in infectious diseases and translational research in HIV and liver disease. She is a standing member of the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline. She is the Vice Dean for Clinical and Translational Research and Director for the Duke Clinical and Translational Sciences Institute.
Current Duke Appointments & Affiliations
Recent Scholarly Works
Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.
Journal article Clin Infect Dis · June 4, 2026 BACKGROUND: We conducted a quadruple-blinded, randomized, placebo-controlled trial of metformin for treating acute SARS-CoV-2 infection to prevent long COVID symptoms in low-risk adults. METHODS: The ACTIV-6 platform evaluated repurposed medications for mi ... Full text Link to item CiteNon-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals.
Journal article Open Forum Infect Dis · May 2026 BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality among people with human immunodeficiency virus (PWH). We aimed to determine the prevalence of MASLD and clinically signif ... Full text Link to item CiteAASLD ISDA Practice Guideline on treatment of chronic hepatitis B.
Journal article Hepatology · April 1, 2026 BACKGROUND AND AIMS: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approa ... Full text Link to item CiteRecent Grants
NIAID Virology Quality Assurance (VQA)
ResearchInvestigator · Awarded by National Institutes of Health · 2026 - 20331/3 CTSA UM1 at Duke University
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2032Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST). A cluster randomized trial of point-of-care hepatitis C testing and treatment among key populations
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2030View All Grants